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Central nervous system tumors take advantage of the unique immunology of the CNS and develop exquisitely complex stromal
networks that promote growth despite the presence of antigen-presenting cells and tumor-inﬁltrating lymphocytes. It is precisely
this immunological paradox that is essential to the survival of the tumor. We review the evidence for functional CNS immune
privilege and the impact it has on tumor tolerance. In this paper, we place an emphasis on the role of tumor-inﬁltrating myeloid
cells in maintaining stromal and vascular quiescence, and we underscore the importance of indoleamine 2,3-dioxygenase activity
as a myeloid-driven tumor tolerance mechanism. Much remains to be discovered regarding the tolerogenic mechanisms by which
CNS tumors avoid immune clearance. Thus, it is an open question whether tumor tolerance in the brain is fundamentally diﬀerent
from that of peripheral sites of tumorigenesis or whether it simply stands as a particularly strong example of such tolerance.
1.Introduction
Central nervous system (CNS) tumors account for high rates
of morbidity and mortality [1]. In children, CNS tumors
represent the most common solid tumors with more than
3100 newly diagnosed patients in the United States annually
[2]. Overall 5-year survival statistics are a dismal 35% in
adult patients while they approach 75% in the pediatric
population [1, 2], likely owing to fundamental diﬀerences
in tumor biology. Even so, more children die each year
from brain tumors—more than 2700 per year [2]—than
from any other cancer. Patients with aggressive CNS tumors
(glioblastoma multiforme, diﬀuse intrinsic pontine glioma,
atypical teratoid/rhabdoid tumor, etc.) fare particularly
poorly due to the high grade inﬁltrative nature of their dis-
ease and fundamental resistance to radiotherapy and current
chemotherapy regimens. In fact, patients with high grade
gliomas generally succumb to progression of persistent or
recurrent disease [3].
CNS tumors may have a specialized immune biology
that allows evasion of immune clearance and promotion
of tumor-growth, and the tissue milieu within which a
CNS tumor naturally grows may be especially important
to supporting this immunobiology. The term “immune
privilege” has been used to describe deﬁcient or defective
adaptive immune responses that translate to an absence of
tumor-speciﬁc immune responses (Table 1). Treatment of
brain cancers is further complicated by the presence of a
small molecule exclusion system, the blood-brain barrier,
which limits the CNS penetration of many chemothera-
peutics. Despite the complexity of this blood-brain barrier,
however,itdoesnotblocklymphocytesormyeloidcellsfrom
migrating to sites of inﬂammation or tumor growth [4, 5].
In fact, brain tumors contain large numbers of tumor
associated macrophages (TAMs) and microglia as well as
tumor inﬁltrating lymphocytes. These cellular components
oftheimmunesystemapparentlycoexistwiththedeveloping
tumor,andwhileantitumorresponsesarepossiblewithinthe
CNS [80], they are typically ineﬀective [38, 81–83]. In fact,
the privileged status that brain tumors enjoy with respect
to immune responses appears to be driven by highly active
and dominant local immune suppression [38, 81, 83], as is2 Clinical and Developmental Immunology
Table 1: Mechanisms of immune privilege.
General peripheral tolerance Ref
T cell negative selection in thymus [6]
Natural (thymic) Tregs [7, 8]
Acquired (adaptive) Tregs [9, 10]
L o c a li m m u n o s u p p r e s s i o n( I D O ,T G F - β,
IL10, CTLA-4) [11–27]
CNS-speciﬁc privilege Ref
Reduced lymphatic transport to draining
lymph nodes [28–33]
Lack of resident immunogenic APCs
(dendritic cells) [28, 29, 34–37]
Specialized endothelium excludes na¨ ıve T
cells [28,29,34,35,38]
Local immunosuppression by astrocytes
and microglia [28, 35, 38–41]
Tumor-induced immunosuppression
(CNS and non-CNS) Ref
Local activation of natural Tregs [7, 42–44]
Tumor-speciﬁc (adaptive) Tregs [42, 44–48]
Local intratumoral immunosuppression
IDO [16, 45, 47–53]




PD-L1 [11, 46, 62, 66]
Myeloid-derived suppressor cells [67–70]
Tolerogenic APCs [42, 44, 45, 47,
48, 61, 71–73]
Tolerogenic draining lymph nodes [45, 47, 48, 73]
Quiescent vascular endothelium [74–79]
Tregs: regulatory T cells; IDO: indoleamine 2,3-dioxygenase; TGF-β:
transforming growth factor-beta; IL10: interleukin-10; CTLA-4: cytotoxic T
lymphocyte antigen-4; PD-L1: programmed death ligand-1; APCs: antigen-
presenting cells.
the case with peripheral solid tumors [45]. However, in CNS
tumors, we speculate that this local tumor-speciﬁc tolerance
may be augmented by the specialized mechanisms of CNS
privilege [28, 39, 84, 85]. Gaining a better understanding
of these tolerogenic mechanisms is critically important
to improving the survivability of malignant CNS tumors,
which currently resist our most aggressive and multimodal
therapeutic strategies.
2. Immune Privilege in the Central
Nervous System
2.1. The Immune Privilege Paradigm. Uncontrolled immune
responses in the brain are more dangerous than in any
other location, and the central nervous system enjoys
a distinctly diﬀerent immunology than peripheral tissues
[29, 34, 35]. Classical CNS “privilege” was described phe-
nomenologically in terms of diminished or absent immune
responses [29, 35]; particularly compelling was Medawar’s
observation that tissue graft rejection was impaired in
the brain [86]. Additional ﬁndings suggesting a unique
immunology existed in the CNS included lack of lymphatic
vessels and lymph nodes within the CNS [29], lack of
dendritic cells resident within the brain parenchyma [29],
lowmajor-histocompatibility (MHC)expressionlevelsonall
cells within the CNS—including low MHC-II on resident
microglia [29, 35] ,a n dw i d e s p r e a dp r e s e n c eo fs o l u b l e
anti-inﬂammatory mediators, such as vasoactive intestinal
peptide [35], alpha melanocyte stimulating hormone [35],
and transforming growth factor-beta (TGF-β)[ 35, 38]. Fur-
thermore, production of inﬂammatory cytokines and nitric
oxide by CNS resident myeloid cells, including macrophages
and microglia, is suppressed by a cell-contact mediated
receptor ligation to CD200, a ligand expressed by brain
parenchymal cells [35]. Thus, the character and strength of
immune responses in the CNS are fundamentally diﬀerent
than in the periphery. Presumably, these strict regulatory
mechanisms [42] have evolved to preserve the nonrepairable
brain tissue and avoid unchecked inﬂammation in a closed
space that could otherwise lead to increased intracranial
pressure, herniation, and death [29].
2.2. Leukocyte Entry into the Central Nervous System. Na¨ ıve
Tc e l l sa r ee ﬀectively excluded from brain parenchyma by
the tight junctions of the blood-brain barrier [28]. Thus,
leukocyte traﬃcking generally occurs at very low frequency
in quiescent brain [35]. Nonetheless, all the elements of
an eﬀective immune response—including dendritic cells,
macrophages, and T cell lineages—can and do traverse the
blood-brain barrier in inﬂammatory states [4, 29, 34, 35].
T cells usually become activated in extra-CNS sites, where
they encounter an appropriate antigen before migrating into
the CNS itself [29, 35]. T cells expressing the chemokine
receptor CCR7 home eﬀectively to the CNS via chemokine-
mediated (CCL19 and/or CCL21) homing [29]. Leukocytes
thus recruited enter the CNS at postcapillary venules by the
standard process of tethering, leukocyte rolling, chemokine
activation, adhesion, and diapedesis [29, 34, 38]. However,
in the CNS, diapedesis appears to occur via transendothelial
extravasation, rather than a paracellular route, which leaves
the blood-brain barrier endothelial tight junctions intact
[29, 85]. Once they have transmigrated through the vascular
endothelium,theseleukocytesﬁndthemselvesinanenlarged
perivascular space, the Virchow-Robin space [29, 34]. It is
within this space that they will either encounter antigen to
maintain their activated state, or fail to do so and die. To
reach the CNS parenchyma, leukocytes still need to cross the
glialimitanswhichisdeﬁnedbytheinterlocking perivascular
astrocyte foot processes [34]. Once in the CNS, however,
activated T cells are free to carry out their eﬀector functions
[35].
2.3. Antigen Presentation in the Central Nervous System. A
unique anatomical facet of CNS immunology is the lack
of local draining lymph nodes. In fact, animal experiments
have shown that labeled dendritic cells injected directly
into CNS parenchyma do not appear to migrate from theClinical and Developmental Immunology 3
site of inoculation [30], whereas dendritic cells (DCs) in
the interstitial ﬂuid of the CNS behave more like DCs in
peripheral sites and are able to migrate to the cervical lymph
nodes via perivascular channels [31]. Other studies have
shown that rat dendritic cells and microglia injected into the
striatum migrate to the perivascular space and exit through
the vasculature to reach distant sites, such as spleen and
mesenteric lymph nodes [32]. In contrast, dendritic cells
injected into the cerebral spinal ﬂuid (CSF) migrate to the B
cell follicles of cervical lymph nodes [30], and they do so by
traversing the cribriform plate to reach the nasal lymphatics
[31]. This is similar to experiments in which radio-labeled
protein infused into the CSF preferentially drains to deep
cervical lymph nodes via the cribriform plate [28, 33].
Thus, the aﬀerent arm of local CNS immune surveillance is
quite complex and, in some contexts, may bypass traditional
lymphatic routes of antigenic sampling.
Not only do antigen-presenting cells (APCs) in the brain
often fail to migrate into lymph nodes, but the CNS is also
the only tissue with microglia as antigen-presenting cells,
which imparts a unique immune biology to CNS-directed
responses [36]. Microglia are derived from early monocytic
cells during embryonic development [34, 37]. In adults and
children, they can be replenished from progenitor cells in the
CNS that have proliferative capacity for microglial renewal
[34]. Microglia resemble resident perivascular macrophages
with similar phenotypic markers and functional proﬁles
[37]. Although resting microglia have a quiescent phe-
notype with low expression of MHC and costimulatory
molecules, they have very dynamic motility, presumably
consistent with their antigen-surveillance function [36]. In
fact, eﬀective responses to viral encephalitis depend upon
microglial cytokine-mediated macrophage recruitment [34].
This cytokine production can lead to capillary leak and
compromise the integrity of the blood-brain barrier [34],
but such a breach will also cause local microglial activation
and recruitment of circulating immune cells [36]. Thus,
microglia play an important regulatory role in initiating
responses to CNS infection and in modulating and directing
intracranial immune responses.
3. Immune Privilege in the Setting of
Central Nervous System Malignancy
3.1. General Events in Tumor Formation, Growth, and Sur-
vival. Tumors must develop complex stromal networks that
promote vigorous growth but suppress adaptive immune
responses—and tumors must accomplish this despite the
presence of many intratumoral innate immune cells and
tumorinﬁltratinglymphocytes[87,88].Thestromalcontent
of solid tumors is very large [89] (sometimes more stromal
cells than tumor cells) and the paradoxical ability of this
stroma to support growth yet suppress immune rejection is
essential to the survival of the tumor.
3.1.1. Important Factors in Oncogenesis. Malignant trans-
formation occurs when a critical mass of genomic and
epigenetic mutations leads to uncontrolled cell division,
either dominated by a loss of cell cycle control [90–93]
or by a defect in apoptotic pathways [92, 94–96]. This
results in a cluster of neoplastic cells, derived from a single
progenitor, which grow without the constraint of normal
anatomicalortissue-speciﬁclimitations.Thesechangesoften
coincide with a dediﬀerentiated phenotype that may be a
distinct consequence of the underlying genetic defects. At
this early stage, potentially immunogenic tumor-associated
shared “self” antigens [97] and truly foreign neoantigens
[97, 98] ﬁrst appear as epitopes found within proteins
derived from mutated or dysregulated genes. Thus, in order
tobecomeestablished,grow,andprogress,CNScancersmust
evade the immune system even at this early stage.
3.1.2. Important Events in Tumorigenesis. Tumorigenesis
is the process by which nascent oncogenic cell clusters
transform into a viable tissue environment with a secure
vascular supply and robust stromal elements capable of
supporting the rapid and sustained tumor tissue growth.
This transformation involves a complex series of events.
Firstly, stromal elements must be recruited and developed
into a subtumoral compartment that serves as a scaﬀold
and provides crucial growth factors leading to angiogenesis
and tumor tissue maintenance [56–58, 67–69, 71, 99, 100].
This stroma must be capable of supporting and promoting
a dominant local immune suppression that leads ultimately
to crucial tumor tolerance [11, 43, 62, 87, 101–106].
Furthermore, this tolerance, and the stroma that supports
it, is characterized by a paradoxical inﬂammatory milieu
that consists of chronic, low-grade, specialized inﬂamma-
tion, which we speculate may drive a characteristic “tissue
remodeling” program that is normally meant for sterile
wound healing, and which is actively suppressive for de
novo T-cell responses within that milieu [59, 67–69, 71,
74, 88, 99, 107–110]. Thus, tumor survival is dependent
upon these closely related and complimentary mechanisms:
stromal formation and angiogenesis, immune suppression
leadingtotheestablishmentoftolerance,andmaintenanceof
bothofthesebyaparadoxicalinﬂammatoryprogramusually
reserved for sterile wound healing (Figure 1).
3.1.3. Stromal Formation and Angiogenesis. Development of
vascular access for nutrient delivery is essential for early
cancercellclusters to develop into a tumor capableof further
growth. Thus, the developing tumor must attract primitive
stromal elements that can provide the foundation for
tumor vascularization. This requirement deﬁnes the tumor
microenvironment as an inﬂammatory tissue environment
where chemokines [67, 68, 71, 88, 100, 108], cytokines [59,
67–69, 71, 74], and various growth factors [67, 68, 74, 87,
107, 109, 110] provide critical signals for migrating stromal
elements—myeloid cells, vascular and lymphatic endothelial
cells, pericytes, ﬁbrocytes, ﬁbroblasts, ﬁbroblastic reticular
cells, and so forth—to take up residence and functionally
support tumorigenesis in the periphery. Once present, many
of these stromal cell types, such as vascular [74]a n d
lymphatic [75] endothelial cells, can engage in proliferation
and can, themselves, secrete chemokines, cytokines, and
growth factors to support the everincreasing stromal needs
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Figure 1: Viable tumor environment. Tumor survival is dependent upon an exquisite interplay between the critical functions of stromal
development and angiogenesis, local immune suppression and tumor tolerance, and paradoxical inﬂammation. TEMs: TIE-2 expressing
monocytes; “M2” TAMs: tolerogenic tumor-associated macrophages; MDSCs: myeloid-derived suppressor cells; pDCs: plasmacytoid
dendritic cells; co-stim.: co-stimulation; IDO: indoleamine 2,3-dioxygenase; VEGF: vascular endothelial growth factor; EGF: epidermal
growth factor; MMP: matrix metaloprotease; IL: interleukin; TGF-β: transforming growth factor-beta; TLRs: toll-like receptors.
of the tumor microenvironment recruits a complex stromal
network to promote tumor growth and tissue remodeling as
necessary. In fact, tumor tissue remodeling is necessary for
the initiation of angiogenesis and occurs in a dynamic fash-
ion [74], with a downregulation of antiangiogenic secreted
proteases, such as ADAMTS-8 in brain tumors [107], and
increased secretion of proangiogenic matrix metalproteases
(MMPs), such as MMP2 and MMP9 [58, 67].
Many tumors, including gliomas, are capable of secreting
other growth factors, such as vascular endothelial growth
factor (VEGF) [72, 91], TGF-β [56–59], and progranulin
[109, 110]. However, the intricate and crucial process of
angiogenesis is mediated largely by CNS tumor inﬁltrating
macrophages [67, 68]a n dm i c r o g l i a[ 56–58]. In fact, sev-
eral tumor-associated macrophage subsets directly promote
angiogenesis. Tumor-associated macrophages of the tolero-
genic“M2”phenotypedriveangiogenesisbysecretingVEGF,
MMP9, epidermal growth factor (EGF), and interleukin-
8( I L 8 )[ 67, 71]. Although their exact role in angiogene-
sis remains to be elucidated, Tie-2 expressing monocytes
(TEMs) inhabit perivascular areas where Tie-2 serves as
the receptor for angiopoietins [67, 68, 71]. Other, more
heterogeneous myeloid populations involved in angiogenesis
include hemangiocytes described as expressing CXCR4,
VEGF receptor-1, Tie-2, Sca-1, and CD117 [67, 68]a n d
myeloid-derived suppressor cells (MDSCs) which express
CD11b, Gr1, and CXCR4 [67–69]. In CNS tumors, resident
brain microglial cells migrate into the developing tumor in
response to the same chemotactic signals that attract the
myeloid subsets [39]. Although not as well studied, it is clear
that microglia also contribute to angiogenesis by secreting
VEGF, EGF, TGF-β,a n dM M P 9[ 57, 72].
3.2. Functional versus Anatomical CNS Privilege. As noted
above, inﬂammatory responses in the CNS are more tightly
regulated than other sites [29, 34, 35, 38, 86]. Historically, it
has been assumed that much of this reduction in immune
responses was a passive anatomical phenomenon, resulting
from the lack of eﬀective antigen-presenting cells and lym-
phatic drainage, combined with anatomic exclusion of circu-
lating lymphocytes by the blood-brain barrier. Given this, it
was natural to assume that CNS tumors partook of a similar,
anatomically-basedprotectionduetotheir“privileged”loca-
tion [28, 111]. Such mechanisms doubtlessly play a role, but
a new paradigm is also emerging, in which CNS tumors also
exploit mechanisms of active immune suppression—both
natural suppressive mechanisms that exist within the CNS
and pathologic immunosuppressive mechanisms induced by
the tumor. Together, these mechanisms allow tumors to
actively protect themselves from immune clearance [28, 42,
111]. The need for active immune suppression becomes log-
ical when we remember that the presence of the tumor itself
often disrupts many of the passive anatomic barriers in the
CNS, for example, by altering the blood-brain barrier in the
tumor vasculature, enhancing leukocyte traﬃcking, creating
chronic inﬂammation, and introducing new populations of
antigen-presenting cells inside the tumor. Thus, tumors in
the CNS are not “invisible” to the immune system, andClinical and Developmental Immunology 5
tumors must actively suppress immune responses against
themselves in order to survive. The importance of under-
standing these active mechanisms of suppression lies in the
fact that active mechanisms represent attractive therapeutic
targets if they can be disrupted.
3.3. Local Immune Suppression and Establishment of Tumor
Tolerance. As tumor size increases, tumor cell turnover also
increases—and so does the volume of tumor-derived anti-
gens. Many of the tumor-associated “shared-self” antigens
could potentially be recognized by the immune system,
because they may be excluded from central tolerance by
virtue of their cellular, anatomical, or developmental expres-
sion patterns [97]. In the case of authentic tumor-speciﬁc
neoantigens, which are derived from the protein products
of mutated genes [97, 98], the immune system by deﬁnition
has never acquired central tolerance. Despite this, however,
the immune system behaves as if it were tolerant to tumor-
derived antigens, whether shared “self” or neoantigens.
One possible hypothesis to explain the lack of immune
response in the presence of large amounts of these potential
immunogens is that, analogous to the processes important
in maintaining adaptive immune tolerance to normal tissues
undergoing rapid cell turnover [112], antigens may be
processed locally in a manner that avoids systemic immune
activation. It appears that the type of APC that processes
these antigens is critically important to the outcome—
tolerance versus stimulation [113]—but the speciﬁc molec-
ular mechanisms by which tolerance is created remain
unclear. Nevertheless, the result can be dramatic: in one
murinespontaneous-tumormodelinwhicheverytumorcell
carries a potently immunogenic xenoantigen, the immune
system still invariably becomes tolerant to the xenoantigen
unless the host is vaccinated against the xenoantigen prior to
tumorigenesis [102].
3.3.1. General Issues Regarding Suppression of Antitumor
Immunity. Autochthonous peripheral tumor models suggest
that tumor-speciﬁc tolerance may become established very
early in tumorigenesis, as observed in mouse models of pan-
creatic ductal adenocarcinoma [101], 4T1 mammary tumors
[43], B16F10 melanoma [43, 45], and AB1 mesothelioma
[43].Thisobservationcanbeexplainedconceptually,inpart,
bythecancerimmunoeditinghypothesisinwhichaninitially
eﬀective antitumor response “edits” the tumor cell repertoire
by removing any cells that are immunogenic [62, 104].
Thus, in this model, the early interactions between immune
cells and tumor cells actively select for later immune sup-
pression by favoring tumor cells capable of escaping immune
clearance.
Some of these escape mechanisms are passive. Passive
tumor escape mechanisms were the ﬁrst to be discovered
and explored, and these include the emergence of tumor cell
antigen-loss variants, downregulation of MHC-I expression,
impairment of antigen processing or MHC binding in
tumor cells, and suboptimal costimulatory molecule expres-
sion on tumor cells [62]. However, more recently, a vari-
ety of active immune suppressive mechanisms have been
identiﬁed, which lead to dominant and profound tumor-
induced tolerance (Table 1) .T h e s ea c t i v em e c h a n i s m s
include secretion of soluble immune-modulating factors by
tumor cells themselves, direct suppression of lymphocyte
activation or eﬀector function, and recruitment of myeloid
or lymphoid suppressor cells. Immunosuppressive cytokines
and growth factors known to be secreted directly by tumor
cells include IL6 [114], IL10 [60], TGF-β [56, 58, 59, 62,
115], and VEGF [62]. These soluble mediators may directly
inhibit T cell activation, and this eﬀect may be augmented by
contact-mediated antagonism of T cell costimulatory path-
ways through ligation of cytotoxic T lymphocyte antigen-
4( C T L A - 4 )[ 11, 62] or the programmed death-1 (PD-1)
receptor on T cells [11, 46, 62]. In fact, one of the PD-1
ligands, PD-L1, is upregulated by gliomas when the PTEN
tumor suppressor gene is defective [66].
Tumors and their stromal components are known to
actively recruit regulatory immune cell subsets [87, 88, 101,
106, 116], especially regulatory T cells (Tregs) [43, 71, 88,
98, 99, 105, 116] .T r e g se x e r td i r e c ts u p p r e s s i v ee ﬀects upon
CD4 T cells and CD8 T cells via secretion of suppres-
sive cytokines (IL10 and TGF-β); consumption of IL2 in
the local microenvironment (which deprives eﬀector T cells
of this critical growth factor); contact-mediated inactivation
of antigen-presenting cells; induction of the immunosup-
pressive enzyme indoleamine 2,3-dioxygenase (IDO) [7,
43, 71], which is discussed below. In addition, activated
Tregs within the tumor microenvironment can polarize
tumor-associated macrophages toward the “M2” suppressive
phenotype[71].ItisclearthatTregsplayanimportantrolein
many tumors, although the degree to which diﬀerent tumors
depend on Tregs probably varies with context.
Despite active suppression of adaptive immune re-
sponses, most tumors appear to have an inﬂammatory
milieu resembling a state of chronic sterile wound healing
[67, 68, 99, 117, 118]. This characteristic tumor-associated
inﬂammation is critical for maintenance of stromal integrity
[99], promotion of angiogenesis [74], and continued tumor
tolerance [88, 99, 108]. While a wide variety of stromal
elements contribute to the formation of this specialized
environment, tumor cells [99, 118] and tumor-associated
macrophages [67, 68, 74, 100, 117] secrete many of the
key inﬂammatory mediators, including the growth factors,
cytokines, chemokines, prostaglandins, and metaloproteases
described above. Elaboration of these crucial factors may
be driven by transcriptional activation caused by oncogenic
mutations [119],toll-likereceptor(TLR)signaltransduction
[99, 118], and/or cytokine- or growth factor-mediated
signaling [74, 99]. Particularly important to the immune
tolerogenic properties of the tumor are the eﬀects of TGF-
β secretion [59], including suppression of T-cell adaptive
and natural killer (NK) cell innate antitumor responses,
recruitment of suppressive myeloid cell subsets such as
suppressive dendritic cells, TAMs, and MDSCs, and recruit-
ment of regulatory T cell activity [7, 12, 59, 73]. As noted
above, vascular [120]a n dl y m p h a t i c[ 75] endothelium may
contribute to this inﬂammatory milieu with growth factors
andchemokines, and it is widely appreciatedthat tolerogenic
“M2” phenotype TAMs support angiogenesis by secreting























Figure 2: Tumor cells and stromal elements with immune suppressive functions. CNS tumor cells, especially glioma cells, may develop the
ability to secrete cytokines including IL6, IL10, and TGF-β and can take advantage of membrane integrin-bound metaloproteases (MMP2
and MMP9) to facilitate motility and invasiveness. Tumor-associated macrophages (TAMs) bind IL6 and IL10 via their respective receptors,
leading to phosphorylation and activation of STAT3, a transcription factor that upregulates TAM IL6, IL10, and TGF-β production and
secretion. Ligation of the CD200 receptor on microglia by the ligand found on parenchymal neurons downregulates inﬂammatory cytokine
and nitric oxide production by microglial cells. Microglial cells also have low expression of MHC-II and secrete IL10 and TGF-β.A s t r o c y t e s
excrete IL10, and also CCL21, thus recruiting activated T cells which are then educated to upregulate CTLA-4 to antagonize costimulatory
signals. IL10 promotes CNS tumor growth and migration, whereas TGF-β is an important regulator of tumorigenesis, angiogenesis, and
tumor cell motility and invasiveness.
3.3.2.InﬁltratingTumor-AssociatedMacrophagesandMicrogl-
ia Maintain the Stromal Microenvironment and Suppress
T-Cell Responses in CNS Malignancy. Tumor-associated
macrophages (TAMs) and microglia are important for
glioma tumor survival (Figure 2), as shown by the fact
that ablation of these cells reduces tumor growth and
improves survival in a murine syngeneic orthotopic glioma
model [83]. TAMs process large volumes of dead and dying
tumor cells without inciting adaptive immune responses,
despite an apparently activated phenotype [67, 68, 71].
Tumor cell turnover is rapid in most solid tumors, and
often the tumor core is devitalized as a result of central
vascular insuﬃciency. This immense ﬂux of cellular debris
must be disposed of; a task that is largely borne by the
tumor associated macrophages (but not, in the case of CNS
tumors, by microglia) [39, 83]. This role for macrophages
in tumors is reminiscent of other tolerogenic macrophage
populations,forexample,marginalzonemacrophageswhich
clear large amounts of apoptotic debris from the splenic
circulation daily; tingible-body macrophages in germinal
centers; Kupﬀer cells which process antigens from the portal
circulation [112]. In none of these cases do macrophages
provoke a pathological immune response to antigens from
the dying cells that they ingest [112].
Theclassictriggerforinﬂammationisinfection,inwhich
activated APCs drive robust lymphocyte responses leading to
pathogen clearance (albeit at the expense of local bystander
tissue damage). However, as described above, certain inﬂam-
matory mediators are also critical to tumor establishment,
growth, progression, and metastasis [68, 83, 117, 121, 122].
These occur in relatively tolerogenic tissue environments
where adaptive immune responses against tumor-derived
antigens have been blunted [100, 123]. This illustrates the
point that the ultimate eﬀects of inﬂammatory mediators
depend not only on the character of the inﬂammation itself
(e.g., sterile wound-healing tissue-remodeling type versus
microbial pathogenic immune stimulation type) [99, 117,
118], but also upon the context in which it occurs (e.g., the
actively immunosuppressive environment of tumors versus
the stimulatory environment of infected tissue) [31, 35, 100,
123].
Outside the CNS, it is known that stromal elements
in tumors can contribute to tumor tolerance. In addition
to the role of macrophages described above, mesenchymal
cells and ﬁbrocytes that express ﬁbroblast activation protein
can drive tumor tolerance independently of TAMs [87]. In
addition, both stromal cancer-associated ﬁbroblasts within
the tumor and mesenchymal ﬁbroblastic reticular cells and
lymphatic endothelial cells in the tumor-draining lymph
nodes are capable of secreting CCL21 [108, 124], which
has been shown to attract CCR7-expressing tolerogenic cell
populations(includingTregsandIDO-expressingcells)[88].
In the specialized environment of the CNS, these and other
stromal cell subsets are normally excluded, and astrocytes
perform many of the comparable stromal functions. As
mentioned above, CNS tumors often disrupt the normal
architecture of the brain, so some of the stroma in brain
tumors may be ectopic, and resemble stroma in peripheral
locations. However, astrocytes also have the ability to
suppress T cell responses—both directly via upregulation of
CTLA-4 expression [40] and by recruitment of regulatoryClinical and Developmental Immunology 7
T cells [125]. Also, CCL21 is secreted by glioma cells and
tumor stromal cells and has been shown to directly promote
glioma cell growth in vitro [83]. Astrocytes may therefore
play a role in stromal-mediated tumor tolerance in the CNS.
Glioma-derivedtumorcellsarecapableofdirectlysecret-
ing immunosuppressive cytokines [35, 39], including IL6
[114], IL10 [60], and TGF-β [56, 115], and microglia and
astrocyteshavealsobeendocumentedassourcesofcytokines
[57, 60]. Serum IL10 levels are elevated in patients with
high-grade glioma, and IL10 enhances glioma cell growth
and migration in vitro [60]. Although high levels of TGF-β
can inhibit glioma cell growth in vitro [115], in vivo TGF-β
plays a role in glioma tumorigenesis, angiogenesis, cellular
motility, and invasiveness [56, 57, 115]. This characteristic
enhancement of invasive potential is mediated by increased
secretion and integrin-mediated glioma cell surface binding
of MMP2 and MMP9 [56, 58]. Cytokines not only aﬀect
the tumor cells, but they also aﬀect the neighboring tumor-
associated macrophages as well. Cytokines such as IL6 and
IL10 bind their respective receptors on the cell surface
of TAMs, leading to phosphorylation and dimerization of
signal transducer and activator of transcription-3 (STAT3).
An autocrine loop is thus established, whereby additional
IL6 and IL10 are produced as a result of their own signal
transduction by TAMs, which also begin to secrete TGF-β
as a result of phospho-STAT3 transcriptional activation [13,
61, 121]. Thus, a mutually reinforcing interplay may exist
between stromal cell- and glioma-derived immune suppres-
sive cytokines, the stromal cells (macrophages, astrocytes,
and microglia), and the glioma cells themselves whereby
tumor-related growth, invasiveness, and immunosuppres-
sion are regulated.
3.3.3. Tumor Tolerance Mediated by Indoleamine 2,3-Dioxy-
genase. Indoleamine 2,3-dioxygenase (IDO) is an intracel-
lular enzyme, involved in tryptophan catabolism, which is
expressed by several murine and human APC subsets that
engage in suppression of T-cell responses [14–24, 45, 47–
49, 126–129]. IDO enzymatic activity degrades tryptophan
via oxidative cleavage of the pyrrole ring, which results
in production of kynurenine as well as other downstream
metabolicproducts,including picolinic acid,quinolinicacid,
and 3-hydroxyanthranilic acid [14, 130, 131]. IDO expres-
sion by specialized plasmacytoid dendritic cells in tumor-
draining lymph nodes directly suppresses local tumor-
speciﬁc T cell responses in the periphery and promotes
activation of regulatory T cells [16, 20–22, 47]. Direct T cell
suppression via IDO-expressing APCs occurs through acti-
vation of the general control nonrepressed-2 (GCN2) kinase
pathway in T cells which are attempting to activate in the
context of insuﬃc i e n tt ryp t o p h a ns t o r e s[ 132]. GCN2 kinase
is part of an integrated stress response pathway that senses
u n c h a r g e dt R N Aa n dl e a d st oa b o r t i v eTc e l la c t i v a t i o n .
Recent work has also implicated the downstream tryptophan
catabolites themselves in suppressing T cell responses by
tumor-inﬁltrating lymphocytes and in experimental models
of autoimmune encephalitis [130, 131].
In a number of peripheral tumor models, IDO appears
to function as a pivotal regulator of tolerance in the tumor-
Figure 3: IDO-expressing astrocytes at the margin of a murine
intracerebralGL261glioma.IDO(red);nuclearcounterstain(blue).
draining lymph node. IDO is expressed by specialized
dendritic cells and other myeloid cells that potently sup-
press T cell responses [16, 18, 133]. Furthermore, IDO
expression by dendritic cells in tumor-draining lymph node
is necessary for certain forms of tumor-induced tolerance,
a phenomenon which occurs in part via recruitment and
induction of existing and new regulatory T cells [48].
Dendritic cells have been shown to drive T cell tolerance
via the IDO pathway in both human [16] and murine
[18] systems. Studies in mouse melanoma have shown that
IDO expression by dendritic cells in draining lymph nodes
suppresses CD8 T cell responses and leads to systemic tumor
tolerance within just a few days [45, 48]. IDO can be induced
bytypeIandtypeIIinterferons,byactivatedTregsviaCTLA-
4 induced ligation of dendritic cell B7 molecules [22]a n db y
STAT3-dependent mechanisms [134, 135].
Most of the preceding studies focused on dendritic cells,
which are notably lacking in CNS tumors. Less is known
about the role of IDO in TAMs and tumor-associated glial
and microglial cells. Several lines of evidence suggest that
IDO may play a role in suppressing CNS tumor-speciﬁc
immune responses. Using immunohistochemistry, Uytten-
hove demonstrated widespread IDO expression in nine
of ten human glioblastoma biopsies. [50]. Human glioma
cells upregulate IDO expression and enzymatic activity in
response to Interferon-γ (IFN-γ)t r e a t m e n tin vitro [136].
IDO expression also can be induced by IFNγ in astrocytes,
microglia, and perivascular macrophages both in vitro and in
vivo as the result of CNS inﬂammation [41]. Furthermore,
intense IDO expression is seen in astrocytes within a reactive
gliosis at the margin of orthotopic murine glioma tumors
(Figure 3), and IDO activity has been documented in
TAMs from a rat orthotopic glioblastoma model using an
immunohistochemical method to stain tissue for quinolinic
acid, a downstream tryptophan metabolite [137]. Thus, IDO
is expressed by many CNS tumors and their associated
stroma, but mechanistic studies are needed to elucidate the
immunologic role of this IDO expression.
3.4. Leukocyte Traﬃcking and Maintenance of Quiescent
Vascular Endothelium within CNS Tumors. Leukocyte entry8 Clinical and Developmental Immunology
into the CNS is tightly regulated and appears to occur only
by transmigration across the endothelium of post-capillary
venules in the choroid plexus, meninges, and CNS
parenchyma [38]. Thus, the most direct route for activated
T cells to reach target tumor cells is transmigration across
vascular endothelium within the tumor itself. This process
is initiated via interactions between vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion molecule-
1 (ICAM-1) on endothelial cells and α4β1-integrin and
leukocyte function-associated antigen-1 (LFA-1), respec-
tively, on T cells [29, 38, 84, 85]. In peripheral tumors,
routine leukocyte margination within the tumor vasculature
is hampered by diminished adhesion to the vessel walls, and
this is thought to be the result of decreased endothelial adhe-
sion molecule expression [76]. Chemo-attractant mediators
may play an important role in activating the endothelial
compartment so that it can support leukocyte binding for
transmigration. Furthermore, leukocytes bearing chemokine
receptors, including CCR1, CCR2, CCR7, and CXCR3, have
been described in various models of CNS inﬂammatory
disease and malignancy [29, 38]. Thus, the tumor may
further shield itself from immune clearance by controlling
thenatureandquantityofcytokineandchemokinesecretion
by stromal elements, including antigen-presenting cells.
Whileendothelialquiescenceisanimportantmechanism
whereby leukocyte traﬃcking into CNS tumors is mini-
mized, CNS tumor vasculature is nonetheless profoundly
aberrant, with signiﬁcant downregulation of endothelial
adhesion molecules [38, 76]. In addition, there is con-
siderable crosstalk between the stromal and endothelial
compartments, which is only complicated by contributions
of the tumor cells and marginated immune cells to the
inﬂammatory milieu. Furthermore, eﬀective angiogenesis
must occur for tumor survival, and this process is mediated
both via VEGF secretion by tumor and stromal cells [38,
39] and by secretion of angiopoietins which sustain and
augment the vasculogenic process by binding the receptor
tyrosine kinase Tie-2, expressed by endothelial lineage
cells [67, 68, 71, 77–79]. In an intriguing departure from
lineage speciﬁcity, glioma-derived stem cells can engage in
vasculogenic mimicry, giving rise to aberrant intratumoral
vascular endothelium [138–143], which has been shown to
be both radioresistant [140] and chemoresistant [141].
4.TherapeuticStrategiesto
Break Immune Privilege
4.1. Vaccination against Brain Tumor-Speciﬁc Antigens. In
the face of the profound tumor-induced tolerance driven
by the mechanisms detailed above, it is not surprising that
attempts to develop vaccination-based immunotherapy have
been met with diﬃculty. In murine brain-tumor models,
vaccines can create early signs of immune responsiveness
(microglial upregulation of MHC, reactive gliosis, and
lymphocyticinﬁltration),butfailtoproducetumorrejection
[80]. More intensive immunotherapy, combining peptide-
pulsed dendritic cell vaccination with tumor-speciﬁc T cell
adoptive transfer, showed that tumor-speciﬁc T cells do
migrate into the brain tumor resulting in smaller tumors
withprolongedsurvival[144].However,theseregimenswere
demanding, requiring sublethal irradiation prior to T cell
transfer and dendritic cell vaccine as well as IL2 cytokine
therapy afterwards.
Clinically, several very promising vaccines have been
developed to target antigens on brain tumors [28]. Unfor-
tunately, vaccination strategies against human glioblastoma
have proven disappointing when used as single-agent ther-
apy. Despite generating apparently robust circulating T
cell responses, vaccines alone do not eradicate the brain
tumors against which they are directed, nor do they provide
gains in survival [81]. More encouragingly, however, when
vaccines against brain tumors are used in conjunction
with chemotherapy, the combination strategy has shown
improvements in median progression-free and overall sur-
vival, although the emergence of antigen loss variants ulti-
mately lead to tumor progression in a large majority of cases
[82]. Thus, the promise of targeted vaccination strategies
for treatment of CNS tumor patients remains an exciting
area of research, but lacks suﬃcient eﬃcacy to qualify as a
standard therapy. For this reason, it is critical to understand
the molecular mechanisms that contribute to tumor-related
immune privilege in the CNS—especially those mechanisms
that may be targeted by available therapeutic agents.
4.2. Pharmacological Blockade of Indoleamine 2,3-Dioxygen-
ase. In various mouse tumor models, pharmacological
inhibition of IDO can transiently break IDO-mediated
tolerance and can improve the eﬀectiveness of a number of
chemotherapeutic agents, in an immune-mediated fashion
[51, 52, 136]. A small molecule inhibitor of the IDO pathway
(1-methyl-D-tryptophan, 1MT) is in Phase I and Phase II
clinical trials for treatment of peripheral tumors in adult
patients [145]. 1MT is not directly cytolytic to tumor cells
[45, 52, 136, 145], but many chemotherapy agents are
known to synergize with 1MT [52]. Recently, 1MT has been
shown to reduce IDO activity in human-derived glioma cell
preparations in vitro without diminishing the cytotoxicity
of standard chemotherapeutic drugs, such as temozolomide
[136]. However, no in vivo studies of 1MT have been
reported, as yet, in preclinical brain-tumor models.
4.3. Antiangiogenesis Therapy. Despite the strong rationale
behind developing antiangiogenic drug candidates [138],
agents such as bevacizumab, a humanized monoclonal
antibody that targets VEGF, have yielded mixed results [3,
146, 147]. Animal studies have shown anti-VEGF therapy
to be eﬀective at compromising glioblastoma perfusion
by eliminating intratumoral vessels [146] via an apoptotic
pathway [147]. However, intratumoral hypoxia appears to
exert selection pressure upon glioma cells, increasing their
invasivepotential[146].Furthermore,clinicaltrialdatashow
conﬂicting results with signiﬁcant extension of progression-
free survival but no improvement in overall survival, relative
to historical controls, in patients treated with bevacizumab
and temozolomide [3]. These observations have raised the
question of whether anti-angiogenic drugs may actuallyClinical and Developmental Immunology 9
compromisedeliveryofadjuvantchemotherapytothetumor
bed and thereby decrease eﬀective glioma drug exposure.
4.4. Other Potential Strategies for Breaking Tolerance to CNS
Tumors. Other agents that may be beneﬁcial for brain
tumor immunotherapy are also approved or in the pipeline.
Contact-mediated antagonism of T cell costimulation by lig-
a t i o no fC T L A - 4[ 11, 62] or PD-1 has been shown to inhibit
tumor-directed T cell responses [11, 46, 62]. PD-L1, one
of the ligands for PD-1, can be expressed by glioma cancer
cells as a protective mechanism [66]. Recently, ipilimumab, a
monoclonal antibody that blocks signaling through CTLA-4,
was approved by the Food and Drug Administration (FDA)
for use in treating metastatic melanoma [63–65], and it has
begunPhaseIIIclinicaltrialsforuseinmetastaticcastration-
resistant prostate cancer [64]. In addition, a monoclonal
antibody that targets PD-1 signaling is in early-phase clinical
trials for solid tumors, including prostate cancer. Although
these drugs have yet to be tested for eﬃcacy in CNS tumors,
they represent promising avenues of immunotherapy that
may be useful in targeting brain tumor tolerance in the
future.
5. Conclusions
Malignant central nervous system tumors are resistant
to standard radiation and chemotherapy following surgi-
cal extirpation. The specialized immunology of the CNS
excludes or attenuates eﬀective immune responses in malig-
nancies. However, despite the complexity of this “CNS
immune privilege”, it is possible to recruit and activate
lymphocytes and myeloid cells under certain conditions.
Gaining a better understanding of CNS tumor-speciﬁc
tolerogenic mechanisms is critically important to improving
the survivability of this disease, which currently resists our
most aggressive and multimodal therapeutic strategies.
Tumor-induced immune tolerance is robust, because
successful tumors have been selected throughout their
existence for their ability to evade the immune system.
Even during the earliest stages of tumorigenesis, when
high cell turnover and availability of tumor shared “self”
antigenshavethepotentialtoawakentheotherwisequiescent
immune system, CNS tolerance mechanisms must be intact
for tumor survival. The specialized stroma of CNS tumors
is likely to be critical to maintenance of immune suppres-
sion within their “sterile inﬂammatory” microenvironment.
Inﬁltrating microglia, macrophages, and astrocytes make up
this stromal milieu and maintain tumor tolerance through
a variety of mechanisms, including secretion of immune
suppressive cytokines and growth factors, suppression of
local T cell responses, and recruitment of regulatory T cells.
Vaccination strategies to recruit the immune system to drive
tumorclearancemustﬁrstovercomethesetolerogenicmech-
anisms. Promising new therapies, such as IDO-inhibitor
drugs and other checkpoint-blockade strategies, used with
vaccines in multimodal combination chemoimmunotherapy
regimens, may allow immunologic therapy of brain tumors
to reach its full potential.
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